PUBLIC COMPANY
save$VERAVera Therapeutics, Inc.
$VERA31.26-3.14%Brisbane, CA, USupdated 4h ago
community read0 votes
pipeline
2
marketed
0
phase 3
0
catalysts ytd
1
approvals ytd
0
recalls ytd
0
Pipeline(2)
pipeline depth2 products
1Phase 21pre_registration
Upcoming
no upcoming catalysts on record
Recent(90d)
earnings (1)
Active trials
- phase2Monthly Dosing of Atacicept in IgAN
- phase2Atacicept in Multiple Glomerular Diseases
- phase3Atacicept in Subjects With IgA Nephropathy
- phase3Atacicept in Subjects With Active Lupus Nephritis (COMPASS)
- phase2A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Atacicept
- phase2A Safety, Pharmacokinetics and Efficacy Study of MAU868 for the Treatment of BK Viremia in Kidney Transplant Recipients
Insider activity
source: SEC Form 4open-market buys + sells
- Apr 14, 26SELLFordyce Marshall· PRESIDENT AND CEO−$617K↗
- Apr 14, 26SELLFordyce Marshall· PRESIDENT AND CEO−$353K↗
- Apr 14, 26SELLFordyce Marshall· PRESIDENT AND CEO−$41K↗
- Feb 23, 26SELLFordyce Marshall· PRESIDENT AND CEO−$711K↗
- Feb 23, 26SELLGrant Sean· CHIEF FINANCIAL OFFICER−$208K↗
- Feb 23, 26SELLYoung Joseph R· SVP, FINANCE, CHIEF ACCT OFFCR−$131K↗
- Feb 23, 26SELLJOHNSON DAVID LEE· Chief Operating Officer−$108K↗
- Feb 23, 26SELLTurner William D.· Chief Regulatory Officer−$92K↗
- Feb 23, 26SELLBrenner Robert· Chief Medical Officer−$90K↗
- Feb 23, 26SELLSkelton Laurence Matthew· Chief Commercial Officer−$66K↗
routine RSU / option mechanics (5)
- Mar 23, 26grantWright-Mitchell Jane · Chief Legal Officer56,850 sh
- Mar 23, 26grantWright-Mitchell Jane · Chief Legal Officer42,403 sh
- Mar 13, 26option exerciseYoung Joseph R · SVP, FINANCE, CHIEF ACCT OFFCR10,000 sh
- Mar 13, 26option exerciseYoung Joseph R · SVP, FINANCE, CHIEF ACCT OFFCR10,000 sh
- Mar 5, 26grantHite Christopher · 24,937 sh
🐶 Hiring Signal
News
- Vera’s newly approved IgA nephropathy drug supports kidney function, like Otsuka’s VoyxactOtsuka Pharmaceuticals’ Voyxact is not the only IgA nephropathy drug that can slow the decline of kidney function. Vera Therapeutics’ Trutakna, which the FDA granted accelerated approval last month…biospace · 3d ago
- Capricor shares spike on CEO comments; Cytokinetics sues Bristol MyersThe FDA is “willing to review” an updated submission for Capricor’s Duchenne cell therapy, its CEO said. Elsewhere, a heart drug battle spilled into court and Rigel priced the first “Protac” medicine.biopharma_dive · 6d ago
- Zealand sells milestone, royalty rights to rare blood cancer asset for up to $100MThe terms of the agreement with Royalty Pharma suggest the market potential of Zealand Pharma’s polycythemia vera drug candidate may be undervalued, according to Jefferies analysts.biospace · 7d ago
- Zealand sells its rights to Takeda’s blood cancer drug for $100M ahead of FDA approval decisionAs the FDA mulls whether to approve Takeda and Protagonist Therapeutics’ rusfertide, Zealand Pharma has sold its own rights to the blood cancer drug in return for $100 million.fiercebiotech · 7d ago
- Silence cashes in on ‘differentiated’ data; UK reaffirms support for childhood vaccinesSome analysts believe Silence’s polycythemia vera drug could be superior to a closely watched Takeda medicine. Elsewhere, the FDA spurned a radiopharmaceutical and AbCellera shares climbed to level…biopharma_dive · 8d ago
- Boulevard Bio dreams big in immunology with $65M, sights on Vera's IgAN drugThough it's no longer unusual for a startup to emerge with an investigational drug from China, an immunology biotech is adding that asset to two disease-controlling drugs it already discovered in-h…endpoints · 8d ago
- Boulevard starts up with $65M to pursue targeted autoimmune drugsCo-founded by pioneering researcher Georg Schett and ex-Sanofi CSO Frank Nestle, the startup is advancing a trio of multifaceted antibodies with the potential to treat several immune diseases.biopharma_dive · 8d ago
- Deerfield-backed Boulevard Bio embarks on ‘beautiful path to a cure’ with trio of immunology drugsBoulevard Bio has strolled out of stealth with $65 million in funding from Deerfield Management and three autoimmune disease candidates.fiercebiotech · 9d ago
- Silence causes uproar in rare blood cancer space as data sets high bar for competitorsThe mid-stage win of Silence Therapeutics’ siRNA drug in polycythemia vera validates the therapeutic approach of similar assets in development—but also sets a high standard for therapies from Taked…biospace · 9d ago
- Silence spells out Phase 2 success for gene-silencing drug in rare blood cancerSilence Therapeutics is set to advance its siRNA drug for the rare blood disorder polycythemia vera (PV) into Phase 3 following a successful mid-stage trial. Silence said Monday that its drug ...endpoints · 10d ago
Data sources
last refreshed 11m ago
Found something off?
comments(0)
5-min edit window · permanent after that